Inovio Pharmaceuticals (INO) to Release Quarterly Earnings on Wednesday

Inovio Pharmaceuticals (NASDAQ:INO) is anticipated to announce its earnings results before the market opens on Wednesday, March 5th. Analysts expect the company to announce earnings of ($0.92) per share and revenue of $0.03 million for the quarter.

Inovio Pharmaceuticals Trading Down 2.0 %

Shares of Inovio Pharmaceuticals stock opened at $1.98 on Wednesday. The company has a market capitalization of $51.68 million, a PE ratio of -0.94 and a beta of 0.89. Inovio Pharmaceuticals has a 12 month low of $1.74 and a 12 month high of $14.75. The stock’s fifty day simple moving average is $2.01 and its 200 day simple moving average is $4.36.

Wall Street Analysts Forecast Growth

INO has been the subject of a number of research reports. HC Wainwright lowered their target price on Inovio Pharmaceuticals from $5.00 to $3.00 and set a “neutral” rating for the company in a report on Monday, January 13th. Oppenheimer decreased their price objective on Inovio Pharmaceuticals from $33.00 to $15.00 and set an “outperform” rating for the company in a report on Monday, November 18th. Royal Bank of Canada decreased their price objective on Inovio Pharmaceuticals from $7.00 to $6.00 and set a “sector perform” rating for the company in a report on Friday, November 15th. Finally, JMP Securities restated a “market outperform” rating and issued a $18.00 price objective on shares of Inovio Pharmaceuticals in a report on Friday, January 10th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, Inovio Pharmaceuticals has an average rating of “Hold” and a consensus target price of $12.40.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.